AVTX - Avalo Therapeutics Inc Price Target Chart
Avalo Therapeutics, Inc (AVTX) relies on early-stage immunological developments, which creates high risks due to the absence of stable sales. The operating model is based on outsourcing production and testing to minimize capital expenditures. The share price history, which currently stands at 34.33, is presented below. The company attracts leading scientists by offering R&D freedom and stock option programs to combat rare pathologies.
Analytical breakdowns for Avalo Therapeutics Inc. (AVTX)
- stock value and consensus price forecast:
- market capitalization statistics:
- issuer book value statistics:
- business debt structure and liquidity details:
Aggregate Debt to Equity Avalo Therapeutics, Inc|AVTX - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital Avalo Therapeutics Inc|AVTX - Company Aggregate Debts|Debts to Book Capitalization Avalo Therapeutics, Inc|AVTX - Company Long-Term Debt|Company Short-Term Loans and Borrowings Avalo Therapeutics|Quick Liquidity Indicator avalotx.com
- earnings and market ratios statistics:
AVTX - Net Profit|Projected Future Earnings Avalo Therapeutics, Inc|AVTX - Price to Earnings Ratio|Future Price to Earnings Multiple Avalo Therapeutics, Inc.|AVTX - PEG Multiple|Total Company Value to Operating Income Before Depreciation Ratio Avalo Therapeutics, Inc|AVTX - Profit before payment of interest, taxes and amortization|Net earnings per share for the last 12 months Avalo Therapeutics|AVTX - Earnings per share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months avalotx.com|AVTX - Net earnings per share growth this year|Earnings growth forecast for next year Avalo Therapeutics, Inc
General company analysis:AVTX avalotx.com
The stability of Avalo Therapeutics, Inc (AVTX) depends on the efficiency of managing external CRO and CMO contractors, which makes the business sensitive to outsourcing operational risks. The average analyst price target for the stock aggregates expert fair value estimates, allowing investors to compare the current quote with the expected growth potential and identify hidden market discounts.
Competitors of Avalo Therapeutics, Inc
Analyst Consensus Forecast argenx.com (ARGX)|BioNTech - Consensus Target|Abivax SA - Price Target Chart|ADMA: Consensus Target|Protagonist Corp - Analyst Forecast Prices|IMVT (Immunovant, Inc.) - Consensus Target|Broker Consensus Forecast KNSA|Price Target Chart Grifols|Adaptive Biotech - Forecast Levels Chart|Analyst Consensus Forecast CLDX|AUPH (Aurinia Corp) - Fair Value Consensus|Analyst Consensus Forecast BCRX (BioCryst)|Analyst Consensus Forecast veratx.com VERA|DNTH - Price Target Chart|Fair Value Consensus PHVS (Pharvaris NV)|AbCellera (ABCL) - Price Target Chart|Consensus Target Tourmaline|PGEN (Precigen, Inc.) - Analyst Consensus Forecast|Analyst Consensus Forecast pharming.com|Consensus Target NKTR (Nektar Therapeutics Inc.)|UPB (Upstream Bio, Inc.) - Fair Value Consensus|Analyst Consensus Forecast ZBIO (Zenas Biopharma, Inc.)|Analyst Median Target Immunome Bio (IMNM)|GOSS - Price Target Chart|kalvista.com (KALV) - Consensus Target|Septerna (SEPN) - Price Target Chart|Consensus Target Pieris Pharma|Consensus Target SVRA|Analyst Consensus Forecast Rigel Corp|Price Target Chart AnaptysBio, Inc. (ANAB)|astriatx.com - Broker Consensus Forecast|Analyst Consensus Forecast ENGN (enGene)|rapt.com (RAPT) - Average Forecast Price|Aerovate - Analyst Consensus Forecast|ACRS - Analyst Consensus Forecast|KYTX (Kyverna Therapeutics) - Consensus Target|TLSA (tizianalifesciences.com) - Price Target Chart|CABA (Cabaletta Bio) - Analyst Consensus Forecast|Analyst Consensus Forecast Ventyx Biosciences Inc.|Price Target Chart Theratechnologies Inc (THTX)|Price Target Chart ELDN (Eledon Pharmaceuticals, Inc)|Price Target Chart Agenus AGEN|climbbio.com (CLYM) - Average Forecast Price|ZURA: Consensus Target|Fair Value Consensus ATYR (aTyr Pharma Inc)|ADAG (adagene.com) - Consensus Target|IMA: Analyst Forecast Prices|STTK (Shattuck Labs Inc) - Analyst Consensus Forecast|EQ: Fair Value Consensus|Analyst Consensus Forecast CNTB|IMUX - Average Forecast Price|Price Target Chart Atara Bio ATRA|Fair Value Consensus IFRX|X4 Pharmaceuticals - Analyst Consensus Forecast|ACET - Analyst Consensus Forecast|celularity.com (CELU) - Price Target Chart|Forecast Levels Chart INMB (INmune Bio Inc)|BRNS (Barinthus Bio) - Analyst Consensus Forecast|Average Forecast Price Kezar Life Sciences Inc KZR|Consensus Target SABS (SAB Biotherapeutics)|Analyst Consensus Forecast akaritx.com (AKTX)|Enlivex Therapeutics Ltd. - Consensus Target|Analyst Forecast Prices QTTB (Q32 Bio Inc)|GeoVax Labs Inc - Analyst Consensus Forecast|Analyst Median Target Edesa Biotech Corp EDSA|IBIO: Analyst Consensus Forecast|Consensus Target Carisma Therapeutics Inc.|Price Target Chart XTL Biopharmaceuticals Ltd.|Bolt Bio (BOLT) - Analyst Median Target|Consensus Target HCWB (HCW Biologics Inc.)|APVO (aptevotherapeutics.com) - Fair Value Consensus|Analyst Consensus Forecast AIM (AIM ImmunoTech)|Analyst Median Target Aditxt Inc. (ADTX)|GRI - Price Target Chart|XRTX (XORTX Therapeutics Inc) - Broker Consensus Forecast|HIND: Analyst Consensus Forecast|Consensus Target Revelation Biosciences Corp|INDP (Indaptus Therapeutics) - Analyst Consensus Forecast|Analyst Consensus Forecast scinai.com|Consensus Target CALI (CalciMedica, Inc.)|Price Target Chart AFMD (affimed.com)|Allakos - Consensus Target|Analyst Forecast Prices HOOK (HOOKIPA Pharma, Inc.)|IGMS: Consensus Target|ITOS (iteostherapeutics.com) - Broker Consensus Forecast|Ocean Biomedical (OCEA) - Price Target Chart|Forecast Levels Chart TCBP (TC BioPharm (Holdings) Plc)|THRD (Third Harmonic Bio, Inc) - Analyst Consensus Forecast
